Novonesis (Novozymes) BFRA:NZM +2.75%90 Days Payable is 73.87 as of Mar. 2026, which is 2% below its 10-year median of 75.18. GuruFocus rates FRA:NZM with a GF Score™ of 90/100 and a GF Value™ of €55.83 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,550 Chemicals companies, Novonesis (Novozymes) B ranks better than 54.19% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B Days Payable vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Days Payable distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Novonesis (Novozymes) B's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B (FRA:NZM) has a Days Payable of 73.87 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novonesis (Novozymes) B and its competitors. This is near median its historical median of 75.18. Over the past decade, Novonesis (Novozymes) B's Days Payable has ranged from 57.70 to 82.09. According to the industry distribution chart, Novonesis (Novozymes) B ranks #710 out of 1550 companies in the Chemicals industry, placing it in the top 45.8%.
Is Novonesis (Novozymes) B's Days Payable too high?
Novonesis (Novozymes) B's current Days Payable of 73.87 is near median its 10-year median of 75.18. Over the past 10 years, this metric has ranged from a low of 57.70 to a high of 82.09. The Chemicals industry median Days Payable is 59.80. Novonesis (Novozymes) B's value of 73.87 is 23.5% above this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #710 out of 1550 companies in the Chemicals industry, which is above the industry midpoint. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Days Payable compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #710 out of 1550 companies for Days Payable. This puts Novonesis (Novozymes) B in the upper half of its industry. The industry median Days Payable is 59.80. Novonesis (Novozymes) B's value of 73.87 is 23.5% above this benchmark. Historically, Novonesis (Novozymes) B's own Days Payable has ranged from 57.70 to 82.09 over the past decade. While the company's 10-year median is 75.18 vs. the industry median of 59.80, Novonesis (Novozymes) B has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Chemicals company?
The median Days Payable among Chemicals companies is 59.80, based on 1,550 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current Days Payable of 73.87 is 23.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median Days Payable is 59.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current Days Payable is 73.87, which is near median its own 10-year median of 75.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (FRA:NZM) is currently considered Fairly Valued. The stock's GF Value™ is €55.83, compared to a current price of €56.00 — trading 0.3% above its estimated fair value. The current Days Payable is 73.87, which is near median its 10-year median of 75.18 and 23.5% above the Chemicals industry median of 59.80. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Novonesis (Novozymes) B (FRA:NZM), the current Days Payable is 73.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (FRA:NZM) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued.
The current stock price of €56.00 is trading 0.3% above its estimated GF Value™ of €55.83.
GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.
Key valuation signals for FRA:NZM:
Days Payable: 73.87 (near median its 10-year median of 75.18)
GF Value™: €55.83 vs. price of €56.00 (0.3% above fair value)
Industry Position: 23.5% above the Chemicals median (#710 of 1550)
No single metric tells the full story. See the FRA:NZM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
90GF Score
Get the complete analysis for FRA:NZM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NZM has been successfully added to your 
